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Abstract
Background: The primary aim of this study is to demonstrate the feasibility of utilizing doxycycline
to suppress matrix metalloproteinase-9 (MMP-9) in brain arteriovenous malformations (AVMs).
Methods: Ex-vivo treatment of AVM tissues: Intact AVM tissues were treated with
doxycycline for 48 hours. Active and total MMP-9 in the medium were measured. Pilot trial: AVM
patients received either doxycycline (100 mg) or placebo twice a day for one week prior to AVM
resection. Active and total MMP-9 in BVM tissues were measured.
Results: Ex-vivo treatment of AVM tissues: Doxycycline at 10 and 100 µg/ml significantly
decreased MMP-9 levels in AVM tissues ex-vivo (total: control vs 10 vs 100 µg/ml = 100 ± 6 vs 60
± 16 vs 61 ± 9%; active: 100 ± 8 vs 48 ± 16 vs 59 ± 10%). Pilot trial: 10 patients received
doxycycline, and 4 patients received placebo. There was a trend for both MMP-9 levels to be lower
in the doxycycline group than in the placebo group (total: 2.18 ± 1.94 vs 3.26 ± 3.58, P = .50; active:
0.48 ± 0.48 vs 0.95 ± 1.01 ng/100 µg protein, P = .25).
Conclusions: A clinically relevant concentration of doxycycline decreased MMP-9 in ex-vivo AVM
tissues. Furthermore, there was a trend that oral doxycycline for as short as one week resulted in
a decrease in MMP-9 in AVM tissues. Further studies are warranted to justify a clinical trial to test
effects of doxycycline on MMP-9 expression in AVM tissues.
Background
Brain arteriovenous malformations (AVM) represent a rel-
atively infrequent but devastating source of neurological
morbidity in relatively young adults [1]. Prevention of
new or recurrent intracranial hemorrhage (ICH) is the pri-
mary rationale for treating AVMs. The optimal manage-
ment of AVMs is not well defined, and the risk of
aggressive surgical therapy can be significantly high. There
is a subset of AVM patients that are considered to be inop-
erable due to the location and size of their lesions [2]. To
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date, there is no clinically available pharmacological treat-
ment of inoperable AVMs to decrease the rate of sponta-
neous intracranial hemorrhage.
Matrix metalloproteinases (MMPs), a family of proteo-
lytic enzymes, degrade extracellular matrix proteins, cell
surface molecules, and other peri-cellular substances [3].
Excessive degradation of the vascular matrix by MMPs
may result in the destabilization of the blood vessel that
potentially leads to weakening of the vessel wall, passive
dilatation, and rupture [4]. Previously, we reported
increased levels of MMP-9 activity in AVMs that may result
in vascular instability associated with growth and
bleeding.
There is an increasing interest in utilizing MMP inhibitors
in treating vascular diseases including abdominal aortic
aneurysms. Doxycycline is a clinically available antibiotic
agent that possesses non-specific inhibitory effects on var-
ious MMPs, and for years it has had a well-established
safety record in treating infectious diseases.
The primary aim of this study is to demonstrate the feasi-
bility of utilizing doxycycline as an MMP inhibitor to
decrease MMP-9 activity in AVMs and potentially decrease
the rate of spontaneous hemorrhage. This exploratory
investigation supports the concept that further studies be
conducted to document the ability of tetracycline and its
derivatives to decrease MMP-9 levels in AVM nidal tissue.
Such a demonstration could provide a firm rationale for
proceeding with clinical trials to test the hypothesis that
tetracycline and its derivatives are useful to decrease the
rate of spontaneous hemorrhage from AVMs in otherwise
untreatable patients or in those awaiting interventional
treatment.
First, we demonstrate that doxycycline can decrease MMP-
9 activity in cultured AVM tissues as a proof of the con-
cept. Further, we present results from a pilot clinical study
demonstrating effects of oral doxycycline treatment on
MMP-9 expression in AVM tissues.
Methods
Ex-vivo treatment of cultured AVM tissues
After institutional review and informed consent, we
obtained AVM specimens after microsurgical resection.
AVM nidus was dissected away from any adjacent brain
tissue in the operating room and a representative portion
of nidus tissue was used for ex-vivo treatment. Ex-vivo cul-
ture of AVM tissue was performed using previously
described method with modifications [5].
AVM tissues were minced into 1–2 mm fragments and vig-
orously washed with phosphate buffered saline (PBS).
Blood cells dissociated from the tissues were removed by
filtration. AVM tissue fragments were placed onto cell cul-
ture inserts and immersed in cell culture medium. During
the first 24 hours, AVM tissues were incubated in DME H-
21 medium containing 10% fetal bovine serum (FBS) to
aid in tissue recovery. Following this recovery period, tis-
sue debris and dissociated cells were removed, and AVM
tissues were incubated in DME H-21 medium containing
1% FBS for 4 hours. The tissue fragments were equally
divided into 12–24 wells. Then AVM tissues were incu-
bated in the medium containing PBS (control) or doxycy-
cline (1, 5, 10 and 100 µg/ml). Each group included 3–5
wells. Size of the tissues dictated a number of treatment
groups in each specimen.
Medium from each well was collected after 48 hours.
Active and total MMP-9 were measured using substrate
zymography. Medium was mixed with SDS sample buffer
(Invitrogen, Carlsbad, CA, U.S.A.) and separated under
non-reducing conditions in a 10% zymogram gel (Invitro-
gen) containing 0.1% gelatin incorporated as a substrate.
Recombinant MMP-2 and MMP-9 proteins (R&D sys-
tems) were used as positive controls. After running, the gel
was incubated with renaturing buffer (Invitrogen). The gel
was then incubated with developing buffer (Invitrogen)
overnight at 37°C. The gel was then stained with colloidal
blue stain (Invitrogen). Proteolytic bands in the zymo-
gram gels were quantified using Image J Software (NIH).
Tissue viability was assessed by measuring the amount of
LDH (lactate dehydrogenase) released in the medium
according to the manufacturer's instructions (Roche, Pen-
zburg, Germany). Some of the tissue fragments were
embedded in paraffin for histological assessment.
Pilot clinical study
Fourteen AVM patients received either 100 mg of doxycy-
cline or placebo twice a day for one week, prior to elective
AVM resection. During the AVM resection, AVM tissues
were collected, and nidus tissues were frozen in liquid
nitrogen. Frozen tissues were stored at -80°C until analy-
sis. Clinical data were collected as previously described
[6].
The specimens were homogenized and insoluble materi-
als were removed by centrifugation at 3000 rpm for 5
minutes. We used total MMP-9 ELISA kit (R&D) and
active MMP-9 ELISA kit (Amersham).
Statistical analysis
Data are presented as mean ± standard deviation. The data
for total MMP-9 and active MMP-9 from ex-vivo AVM tis-
sues are presented as a relative expression with control
brain samples as 100%. We used ANOVA for comparison,
and statistical significance was taken at P < .05.BMC Neurology 2005, 5:1 http://www.biomedcentral.com/1471-2377/5/1
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Results
Ex-vivo treatment of cultured AVM tissues
We collected two AVM tissues for ex-vivo treatment with
doxycycline. These patients were not enrolled in the pilot
clinical study.
AVM-I
AVM tissue-I was collected from a 28 y.o. patient with a 29
mm AVM (Spetzler-Martin score 3). The patient had an
AVM hemorrhage 236 days prior to the AVM resection.
The patient did not receive embolization treatment or
radiosurgery. AVM tissue-I was divided into 9 wells and
treated with 0, 10, and 100 ng/ml of doxycycline (3 wells
for each). Two doxycycline doses were selected to test (1)
whether an average doxycycline concentration (10 ng/ml)
achieved by standard clinical treatment has any effects on
MMP-9 in AVM tissue, and (2) whether a high concentra-
tion of doxycycline (100 ng/ml) has any effects of viability
of AVM tissues in vitro.
There was a gradual increase in LDH release over the
course of 8 days, indicating continuous cellular death and
a gradual decrease in tissue viability (Figure 1). However,
there was no difference among different treatment groups.
To avoid effects from ongoing cellular death and to ensure
tissue viability during the treatment, we chose the first 48
hours to assess the effects of doxycycline on MMP-9 levels
in AVM tissues.
Tissue integrity was further assessed by examining H&E
staining of ex-vivo cultured tissues (Figure 2). On day 0
(before the treatment), although cutting and mincing of
the AVM tissues had caused minor tissue injury and dis-
tortion, a majority of blood vessels were intact and viable.
On day 2 (after 48 hours of treatment), blood vessels were
still intact and viable, and there was no apparent necrosis
or hyalinization of the tissues. However, on day 7, a major
part of the tissues, especially tissues surrounding blood
vessels were anuclear and hyalinized, indicating that tis-
sues were not intact or viable anymore.
Doxycycline 10 µg/ml and 100 µg/ml significantly
decreased active MMP-9 (control vs doxycycline 10 µg/ml:
100 ± 8 vs 48 ± 16%-control, P < .05; control vs doxycy-
cline 100 µg/ml: 100 ± 8 vs 59 ± 10%-control, P < .05)
(Figure 4A). In addition, there was a significant reduction
of total MMP-9 by doxycycline at 10 and 100 µg/ml (con-
trol vs doxycycline 10 µg/ml: 100 ± 6 vs 60 ± 16%-control,
P < .05; control vs doxycycline 100 µg/ml: 100 ± 6 vs 61 ±
9%-control, P < .05). (Figure 4B) There was no difference
in active MMP-9 and total MMP-9 between doxycycline at
10 µg/ml and 100 µg/ml. A representative zymogram is
shown in Figure 3.
AVM-II
AVM tissue-II was collected from a 63 y.o. patient with a
22 mm AVM (Spetzler-Martin score 2). The patients had a
history of AVM hemorrhage 167 days prior to the AVM
resection. The patient received an embolization treatment
1 day before the AVM resection. The patient did not
receive radiosurgery.
Using this tissue, we aimed to study effects of doxycycline
at more clinically relevant concentrations of doxycycline
(1–10 µg/ml). Therefore, AVM tissue-II was treated with 0,
1, 5, and 10 µg/ml of doxycycline for 48 hours. Since the
results from AVM tissue-I showed a relatively wide varia-
tion in MMP-9 levels in each well among the same treat-
ment group, we increased wells per treatment group from
3 to 4.
There was no difference in tissue viability indicated by
LDH release among different treatment groups at 48
hours (data not shown). Similar to the AVM-I, doxycy-
cline 10 µg/ml significantly decreased active and total
MMP-9 (active MMP-9: control vs doxycycline 10 µg/ml:
100 ± 54 vs 43 ± 15%-control, P < .05; total MMP-9: con-
trol vs doxycycline 10 µg/ml: 100 ± 41 vs 59 ± 21%-con-
Tissue viability assessed by LDH (lactate dehydrogenase)  release Figure 1
Tissue viability assessed by LDH (lactate dehydroge-
nase) release. There was a gradual increase in LDH release 
(mean ± SD) over the course of 8 days, indicating continuous 
cellular death and a gradual decrease in tissue viability. How-
ever, there was no difference among different treatment 
groups.BMC Neurology 2005, 5:1 http://www.biomedcentral.com/1471-2377/5/1
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trol, P < .05) (Figure 4C &4D). In addition, there was a
trend for doxycycline 1 and 5 µg/ml to decrease active and
total MMP-9.
Pilot clinical trial
14 AVM patients were enrolled. The trial was originally
started as a double blinded randomized trial, and 9
patients were randomized. In an effort to improve recruit-
ment for this feasibility study, we converted to an open
label drug design.
10 patients received doxycycline, and 4 patients received
placebo. Clinical data are shown in Table 1. Subjects were
informed regarding possible side effects including gas-
trointestinal symptoms, cutaneous photosensitivity, skin
pigmentation, teeth discoloration, and vestibular side
effects. To monitor compliance and possible side effects,
study subjects were interviewed by phone three times dur-
ing one-week treatment period. One patient had nausea
that was relieved by taking food with the drug. Other side
effects were not noted.
There was a trend for both total MMP-9 and active MMP-
9 levels to be lower in the doxycycline group than in the
placebo group (total MMP-9: 2.18 ± 1.94 vs 3.26 ± 3.58
ng/100 µg protein, P = .50; active MMP-9: 0.48 ± 0.48 vs
0.95 ± 1.01 ng/100 µg protein, P = .25) (Figure 5).
Discussion
In this study, we demonstrated the feasibility of doxycy-
cline, a tetracycline derivative, to decrease MMP-9 activity
in AVM tissues. First, we demonstrated that a clinically rel-
evant concentration of doxycycline decreased MMP-9
without affecting tissue viability in ex-vivo AVM tissues.
Second, there was a trend that oral administration of dox-
ycycline for as short as one week in AVM patients resulted
in a decrease in MMP-9 at the target site – in the AVM
nidus. By decreasing MMP-9 activity in AVM tissues, dox-
ycycline may be able to restore the structural stability of
AVM blood vessels and modify the clinical course of
AVMs. Our data will provide the basis to conduct a clinical
study to assess effects of tetracycline derivative treatment
on the prevention of hemorrhage from AVMs.
MMP-9 is a major enzyme that degrades the vascular
extracellular matrix and has been implicated in a number
of vascular diseases that involve abnormal angiogenesis
and vascular remodeling [7]. MMPs are reported to be
increased in cerebral aneurysms, atherosclerotic carotid
plaque, and abdominal aortic aneurysm [8-10]. MMPs are
emerging as a potentially new therapeutic target to treat
vascular diseases. It has been proposed that pharmacolog-
ical inhibition of MMPs may stabilize the unstable blood
vessels and prevent complications such as vessel rupture
[7]. In patients with abdominal aortic aneurysm, doxycy-
cline treatment for one week prior to the repair surgery
resulted in decreased MMP-9 and MMP-2 in the wall of
the aneurysms [10]. Similar results have been reported in
patients with atherosclerotic carotid plaques who received
doxycycline for 2–8 weeks [11].
Our data using ex-vivo AVM tissues showed that abnor-
mally high levels of MMP-9 expression in AVM tissues
could be reduced by a clinically relevant concentration of
doxycycline (i.e. 1–10 µg/ml). In patients with abdominal
aortic aneurysm, doxycycline treatment at a conventional
dose, 200 mg/day, resulted in a mean plasma concentra-
tion of doxycycline at 4.6 µg/ml with a range of 1.3 to 14.4
H&E staining of ex-vivo cultured AVM tissues Figure 2
H&E staining of ex-vivo cultured AVM tissues. On day 0 (before the treatment), although cutting and mincing of the 
AVM tissues appeared to cause minor tissue injury and distortion, a majority of blood vessels was intact and viable. On day 2 
(after 48 hours of treatment), blood vessels were still intact and viable, and there was no apparent necrosis or hyalinization of 
the tissues. However, on day 7, a major part of the tissues, especially tissues surrounding blood vessels were anuclear and hya-
linized, indicating that tissues were not intact or viable anymore.BMC Neurology 2005, 5:1 http://www.biomedcentral.com/1471-2377/5/1
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µg/ml in humans, and there was a corresponding reduc-
tion in plasma MMP-9 levels [12]. Similar plasma levels of
doxycycline in mice successfully inhibited growth of
experimental abdominal aortic aneurysms [13]. We were
able to show that doxycycline at 10 µg/ml for as short as
48 hours can reduce MMP-9 expression in AVM tissues. A
longer duration of treatment often used in clinical settings
may result in a more pronounced reduction in MMP-9
expression in AVM tissues.
One of the limitations of the ex-vivo study was the rela-
tively short duration of doxycycline treatment. We chose
48 hours treatment to ensure tissue viability and integrity.
Although we chose the doxycycline concentrations based
on plasma doxycycline levels achieved by a commonly
used therapeutic regimen, it is possible that tissue levels of
doxycycline might be significantly lower than those of
plasma. Furthermore, functional consequences of the
reduction of MMP-9 in AVMs need to be examined in ani-
mal models or clinical studies. However, at the present
time, there is no animal model that approximates recur-
rent intracranial hemorrhage from AVMs. There are mod-
els that can mimic certain aspects of the AVM phenotype.
Hyperstimulation of mouse brain with VEGF using aden-
oviral transduction causes an increase in capillary density,
increased MMP-9 activity, and may, in the appropriate
genetic background, result in small vascular malforma-
tions [14]. Doxycycline can reduce capillary density and
MMP-9 activity in this model [15].
Doxycycline has been shown in other human vascular dis-
eases to reduce MMP levels. For example, Axisa et al.
treated patients undergoing carotid endarterectomy with
doxycycline or placebo for 2–8 weeks. Although MMP-1,
Representative zymogram showing MMP-9 and MMP-2 standard, control AVM tissues, AVM tissues treated with 10 µg/ml dox- ycycline, and AVM tissues treated with 100 µg/ml doxycycline Figure 3
Representative zymogram showing MMP-9 and MMP-2 standard, control AVM tissues, AVM tissues treated 
with 10 µg/ml doxycycline, and AVM tissues treated with 100 µg/ml doxycycline. In AVM tissues, there were prote-
olytic bands corresponding to pro-MMP-9 (≈97 kDa) and active-MMP-9 (≈88 kDa).BMC Neurology 2005, 5:1 http://www.biomedcentral.com/1471-2377/5/1
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MMP-3, and MMP-9 were reported to be increased, only
MMP-1 had a statistically significant reduction by doxycy-
cline; there was a trend for MMP-9 to be decreased by
22%. Baxter et al. used a much longer treatment period, 6
months, in patients with abdominal aortic aneurysm.
They reported a gradual reduction of plasma MMP-9 lev-
Active and total MMP-9 levels after 48 hours of ex-vivo doxycycline treatment Figure 4
Active and total MMP-9 levels after 48 hours of ex-vivo doxycycline treatment. AVM-I: Doxycycline 10 µg/ml and 
100 µg/ml significantly decreased active MMP-9 There was a significant reduction of total MMP-9 by doxycycline at 10 and 100 
µg/ml There was no difference in active MMP-9 and total MMP-9 between doxycycline at 10 µg/ml and 100 µg/ml. AVM-II: 
Doxycycline 10 µg/ml significantly decreased active and total MMP-9. There was a trend for doxycycline 1 and 5 µg/ml to 
decrease active and total MMP-9. (mean ± SD)
Table 1: Characteristics of AVM patients enrolled in a pilot clinical study to test effects of oral doxycycline treatment on MMP-9 in 
AVM lesions.
Group Age Gender S-M score* AVM size** Draining veins History of 
hemorrhage
Number of embolization 
treatments
Dox 50 M 4 38 Superficial & Deep No 1
Dox 48 F 4 30 Deep Yes 0
Dox 52 M 4 42 Superficial & Deep Yes 2
Dox 43 M 3 29 Superficial & Deep No 1
Dox 23 M 4 34 Superficial & Deep No 2
Dox 28 M 4 40 Superficial Yes 2
Dox 56 M 2 10 Superficial No
Dox 41 F 3 30 Superficial No 1
Dox 62 M 2 41 Superficial No 1
Dox 42 M 2 2 Superficial Yes 0
Placebo 53 M 2 28 Superficial & Deep No 1
Placebo 17 M 1 18 Superficial No 1
Placebo 48 F 2 13 Deep No 0
Placebo 22 M 3 19 Deep Yes 0
* Spetzler-Martin score (15), **AVM maximum diameter (10). Dox = doxycyclineBMC Neurology 2005, 5:1 http://www.biomedcentral.com/1471-2377/5/1
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els by oral doxycycline over 6 month treatment period
(baseline vs 3 months vs 6 months: 119 ± 38 vs 84 ± 33 vs
66 ± 24 ng/ml) [12].
To further explore the feasibility of a clinical application
of doxycycline in modifying the clinical course of AVMs,
we conducted a pilot clinical trial. This trial was primarily
designed to test the effects of a short-term treatment with
oral doxycycline on the expression of MMP-9 in AVM tis-
sues. Despite the small sample size and short duration of
treatment used in this study, there was a clear trend for
one week of oral doxycycline treatment prior to surgical
resection to reduce expression of both active and total
MMP-9 in AVM tissues. These results indicate the feasibil-
ity of oral treatment with tetracycline derivatives in reduc-
ing MMP-9 activity in AVM tissues.
Despite a large difference in the mean values of MMP lev-
els in our pilot data, variance of MMP levels was high.
Accordingly, a sample size of 46 in each group would be
needed to demonstrate a difference in active MMP-9,
assuming an alpha of 0.05 and power of 80%. However,
variance may be reduced by utilizing a longer duration of
treatment, as suggested by studies in other diseases
[11,12]. A clinical study with a modestly larger sample
size and longer treatment duration should suffice to verify
effects of oral doxycycline on reducing MMP-9 activity in
AVMs.
There are some further considerations that may account
for our high variance that could be avoided in future stud-
ies. Surgical AVM tissues consist mainly from nidal tis-
sues, but they may contain intervening astroglial or
neuronal tissues that may not express angiogenic factors
to the same extent as nidal tissue. Histological examina-
tion of each AVM tissue fragments to confirm a predomi-
nance of nidal tissues may yield more homogenous tissue
and decrease variability in MMP-9 levels. Some of the
homogenized samples underwent a several "thaw-freeze"
processes during the preliminary phase of the experi-
ments, which may have increased variability in MMP-9
levels. Embolization treatment may affect production and
activation of MMPs. Our previous study, however,
showed no association between MMP-9 and
embolization treatment in 37 AVM patients [16]. Based
on the experience from this pilot study, future studies can
be performed in a more standardized fashion to decrease
tissue-to-tissue variability.
We used different methods to measure MMP-9 in the
medium collected from ex-vivo AVM tissues and
homogenized AVM tissues from the pilot clinical trial. We
chose zymography, a gel based method detecting enzy-
matic activity of MMPs, for ex-vivo AVM tissues, because
the medium volume that can be used for MMP-9 assay
was extremely limited, and our preliminary experiments
showed higher sensitivity of zymography compared to
ELISA. One of the disadvantages of using zymography is
that "gel-to-gel" variability in sensitivity makes it difficult
to combine the data obtained from multiple gels. On the
other hand, ELISA method allows researchers to assay
approximately 40 samples at a time when duplicates are
used. In addition, establishing a standard curve, ELISA
method can express MMP-9 expression values by the
absolute unit such as µg/ml or ng/100 µg protein. There-
fore, for the clinical pilot trial, in order to quantitatively
compare MMP-9 expression among a large number of
samples originally planned, we used ELISA to MMP-9
expression.
Conclusions
In summary, results suggest that doxycycline may have a
therapeutic potential to reduce MMP-9 activity in AVM tis-
sues and stabilize blood vessels that are prone to rupture.
Our findings may provide a basis for a larger clinical trial
to study effects of tetracycline derivatives in preventing
AVM hemorrhage.
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Effects of oral doxycycline treatment on MMP-9 in 
AVM tissues. There was a trend for both total MMP-9 and 
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